CCA
GILD icon

Checchi Capital Advisers’s Gilead Sciences GILD Stock Holding History

Checchi Capital Advisers’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,558,400
Closed -$191M – 462
2020
Q1 		$191M Buy
+2,558,400
New +$177M 18.3% 2

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Checchi Capital Advisers's GILD Position: Q2 2026 in Review

Checchi Capital Advisers reduced its Gilead Sciences (GILD) stake by 6.6% in Q2 2026, selling an estimated $91.2K and leaving 9,839 shares worth $1.24M. The position accounts for 0.06% of the portfolio, ranked #183.

Checchi Capital Advisers first reported a position in GILD in Q4 2013 and has held it in 51 quarters since. The position peaked at $1.55M in Q2 2015. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Checchi Capital Advisers held 9,839 shares of Gilead Sciences worth $1.24M as of Q2 2026.
  • Checchi Capital Advisers sold 692 Gilead Sciences shares in Q2 2026, an estimated $91.2K.
  • Gilead Sciences made up 0.06% of Checchi Capital Advisers's portfolio in Q2 2026, its #183 holding.
  • Checchi Capital Advisers first reported a position in Gilead Sciences in Q4 2013 and has held it in 51 quarters since.
  • Checchi Capital Advisers's Gilead Sciences position peaked at $1.55M in Q2 2015.
  • 1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Checchi Capital Advisers's 13F filing for Q2 2026, filed 4 Aug 2026.